Fatty liver is an abnormal metabolic condition of excess intrahepatic fat. This condition, referred to as hepatic steatosis, is tightly associated with chronic liver disease and systemic metabolic morbidity. The most prevalent form in humans, i.e. non-alcoholic fatty liver, generally develops due to overnutrition and sedentary lifestyle, and has as yet no approved drug therapy. Previously, we have developed a relevant large-animal model in which overnourished sheep raised on a high-calorie carbohydrate-rich diet develop hyperglycemia, hyperinsulinemia, insulin resistance, and hepatic steatosis. Here, we tested the hypothesis that treatment with thiamine (vitamin B1) can counter the development of hepatic steatosis driven by overnutrition. Remarkably, the thiamine-treated animals presented with completely normal levels of intrahepatic fat, despite consuming the same amount of liver-fattening diet. Thiamine treatment also decreased hyperglycemia and increased the glycogen content of the liver, but it did not improve insulin sensitivity, suggesting that steatosis can be addressed independently of targeting insulin resistance. Thiamine increased the catalytic capacity for hepatic oxidation of carbohydrates and fatty acids. However, at gene-expression levels, more-pronounced effects were observed on lipid-droplet formation and lipidation of very-low-density lipoprotein, suggesting that thiamine affects lipid metabolism not only through its known classic coenzyme roles. This discovery of the potent anti-steatotic effect of thiamine may prove clinically useful in managing fatty liver-related disorders.
Fatty liver (FL) represents an abnormal metabolic condition of excess intrahepatic fat (>5.5% w/w liver fat fraction), which is also referred to as hepatic steatosis. FL and its association with chronic liver disease (steatohepatitis, cirrhosis and cancer) has long been known to result from excessive alcohol consumption or viral hepatitis (Asselah et al., 2006; Louvet and Mathurin, 2015). However, in recent decades the prevalence of non-alcoholic FL disease (NAFLD), which is largely attributed to excess caloric intake and sedentary lifestyle, has become more significant and is currently estimated to affect ∼25% of the global population (Younossi et al., 2018). To better reflect the tight relationship of NAFLD with systemic metabolic dysfunction, such as insulin resistance and dyslipidemia, and its continuum of liver abnormalities, its coexistence with other liver diseases or concomitant to alcohol consumption, an alternative name, i.e. metabolic dysfunction-associated FL disease (MAFLD), has recently been proposed (Eslam et al., 2020a,b). We have adopted this more-inclusive term in the following.
Despite the increasing prevalence of MAFLD, and the accompanying rise in end-stage liver disease requiring liver transplantation (Goldberg et al., 2017; Wong et al., 2015) and in hepatocellular carcinoma (Mittal et al., 2016), there is as yet no approved drug therapy for the disorder. Although numerous therapeutic strategies are being developed and tested for targeting the steatotic, oxidative, inflammatory, fibrotic and metabolic aspects of MAFLD, the responses observed in clinical trials have so far been inadequate (Friedman et al., 2018). This may reflect the heterogeneous and multifaceted nature of the disease, highlighting the unmet need for more robust preclinical models and for the development of combination therapies (Santhekadur et al., 2018). Likewise, therapeutic agents with the potential to counteract multiple aspects of this complex disorder may be of higher clinical value.
We have recently reported a large-animal nutritional model for FL, characterized by excessive carbohydrate intake, hyperglycemia and hyperinsulinemia, which collectively drove liver steatosis in sheep (Kalyesubula et al., 2020). In a search for a pharmacological intervention with the potential to counteract both the systemic and liver-related metabolic aspects of this model, we decided to investigate thiamine, also known as vitamin B1, as a plausible beneficial agent, because of its fundamental role in energy metabolism. The biologically active form of thiamine is produced by its intracellular phosphorylation to thiamine pyrophosphate (TPP) (Voskoboyev and Ostrovsky, 1982), an essential coenzyme for the catalytic decarboxylation of α-keto acids and transketolase reactions in all forms of life (Manzetti et al., 2014).
Of particular relevance to overnutrition and related metabolic disorders is the role of TPP in mitochondrial catabolism as a coenzyme for pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (α-KGDH). In the decarboxylation of pyruvate to acetyl coenzyme A (acetyl-CoA) by PDH, TPP enables the terminal oxidation of carbohydrate-carbon sources in the tricarboxylic acid (TCA) cycle. Whereas this role places thiamine bioavailability at a pivotal checkpoint between aerobic and anaerobic glucose metabolism, the cofactor role of TPP for α-KGDH, which is involved in the regulation of the turnover rate of the TCA cycle (Huang et al., 2003), emphasizes the importance of thiamine in the catabolism of both carbohydrates and fatty acids.
Regular ingestion of western-style diets, particularly rich in simple carbohydrates, can deplete physiological levels of thiamine (Elmadfa et al., 2001; Lonsdale, 2006; Maguire et al., 2018). Indeed, thiamine deficiency is associated with obesity and diabetes (Eshak and Arafa, 2018; Thornalley and Ali, 2007), and thiamine supplementation reduced hyperglycemia, diabetic complications and oxidative stress (Al-Attas et al., 2014; Alaei Shahmiri et al., 2013; Arvidsson et al., 2003; Babaei-Jadidi et al., 2004; Gorlova et al., 2019; Hammes et al., 2003; Karachalias et al., 2010; Rabbani et al., 2009; Tunc-Ozdemir et al., 2009). In the metabolic context, it has been shown that overproduction of thiamine in Arabidopsis plants increases the oxidation of carbohydrates in the TCA cycle (Bocobza et al., 2013). Taken together, these observations suggest that thiamine concentrations above the normal physiological levels may enhance carbohydrate combustion, presumably although not necessarily exclusively, by maximizing the oxidative activity of TPP-dependent enzymes. Whether such thiamine-dependent action can slow the rate of hepatic fat accumulation by reducing carbohydrate availability for de novo lipogenesis (DNL) and/or by directly increasing fatty acid oxidation in the TCA-cycle remains unexplored.
The strong association between hepatic steatosis and hyperglycemia in the sheep model (Kalyesubula et al., 2020), together with the accumulated evidence in respect to the relevant metabolic benefits of thiamine supplementation, motivated us to investigate the potential of high-dose thiamine treatment to counteract the overnutrition-driven steatosis that develops in this model.
To test the hypothesis that high-dose thiamine treatment can reduce hepatic steatosis, we conducted an experiment in which randomly assigned weaned lambs (N=36) were raised for a total of 135 days under three different regimes (Fig. 1). These were, (i) a low-calorie (LC) diet known to maintain lean livers, (ii) a high-calorie (HC) diet known to stimulate FL (Kalyesubula et al., 2020), and (iii) thiamine-treatment in combination with the HC diet (THC).
Subcutaneous injections of thiamine (300 mg/animal) were initiated on day 50, to allow for some liver fat to build up. Metabolic and physical parameters were weekly monitored in vivo throughout the entire experiment, and the cumulative liver phenotypes were evaluated ex vivo on livers harvested postmortem. Differences between HC and LC animals were ascribed to effects of the diet, whereas differences between THC and HC animals (from day 50 onwards) to the thiamine treatment effects.
To identify molecular signals associated with the observed phenotypes, we employed differential expression analyses of selected genes involved in carbohydrate and lipid catabolism, synthesis, transport and storage, since improper balance between these metabolic pathways may lead to abnormal accumulation of intrahepatic fat (Kawano and Cohen, 2013).
High-calorie diet increased weight gain and adiposity
As expected (Kalyesubula et al., 2020), animals raised on the HC diet gained substantially more weight than those consuming the LC diet (P<0.0001; Table 1, Fig. S1). This increase in body weight was accompanied by significantly greater adiposity compared with animals on the LC diet, as indicated by a higher body mass index (BMI; P=0.003) and a higher body condition score (BCS; P<0.0001), determined on a scale of 1 to 5, ranging from very thin to very fat (Kenyon et al., 2014) (Table 2). On average, THC animals consumed similar or slightly higher quantities of the HC diet than HC animals (Table S1 and Fig. S2A) but tended to weigh less after the same number of days (P=0.09; Table 1, Table S2).
Consistent with adiposity induced by HC diet, HC animals presented with higher levels of fasting plasma leptin than LC animals (P=0.02; Table 2, Fig. S3A). The circulating concentrations of triglycerides (TG) were also significantly higher in HC compared with LC animals (P=0.02; Table 1, Fig. S3B). However, no effects of thiamine on either plasma leptin or TG were detected.
Thiamine raised the liver abundance of TPP, as measured by α-KGDH activity
As expected, thiamine-treated animals displayed higher circulating thiamine concentrations compared to the untreated HC group (P=0.05; Fig. 2A), indicating that the subcutaneous injections of thiamine hydrochloride did, indeed, reach the bloodstream efficiently. However, as this does not prove a concomitant increase of thiamine in tissue, the latter was evaluated through determination of intracellular TPP levels.
Generally, thiamine deficiency is diagnosed by evaluating the response of erythrocytes transketolase activity to exogenous TPP, where higher responses reflect higher deficiencies and vice versa (Mastrogiacomo et al., 1993). To examine the effect of the HC diet and the thiamine treatment on the abundance of TPP in the liver, we employed the same approach and studied the activity of α-KGDH in liver lysates in response to exogenous TPP. We found that α-KGDH activity increased more substantially in HC versus in THC animals in response to exogenous 50 µM TPP (P=0.01; Table 2). Although the response to TPP was not significantly different between THC and LC animals (P=0.3), the response in HC animals trended higher compared with that in LC animals (P=0.08). Taken together, these enzymatic data indicate that the HC diet induced low hepatic levels of TPP, and that thiamine treatment reversed this effect (Fig. 2B).
Thiamine reduced blood glucose and increased liver glycogen levels
As previously observed (Kalyesubula et al., 2020), in contrast to the LC diet, the HC diet induced fed-state hyperglycemia (P<0.0001; Fig. 3A, Table 1). The difference in blood glucose between HC and LC animals during fasting was not as substantial but still statistically different (P=0.01; Table 2). Similarly, steady fed-state hyperinsulinemia was induced by the HC diet (P<0.0001; Fig. 3B). THC animals had reduced blood glucose concentrations compared to the thiamine-untreated HC animals (P=0.02; Fig. 3A, Table 1). Despite its reducing effect on blood glucose levels, thiamine had no detectable effect on the diet-induced hyperinsulinemia (Fig. 3B). Since the average dietary intake was similar, or even slightly higher, in the THC compared to the HC group (Fig. S2), these observations suggest that thiamine-treated animals had enhanced carbohydrate catabolism. Consistently, we found that THC animals had increased mRNA levels (P=0.002; Fig. 3G) of the significant glycolytic factor, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
In line with the high plasma insulin levels observed in both HC and THC animals, the concentration of circulating non-esterified fatty acids (NEFA) were low in these groups compared with the LC group (P<0.0001; Fig. 3C, Table 1), indicative of reduced adipose lipolysis, presumably caused by the high plasma insulin. As previously observed (Kalyesubula et al., 2020), both whole-body and adipose-tissue insulin resistance were increased with the HC diet, as respectively evaluated by homeostatic model assessment of insulin resistance (HOMA-IR; P<0.0001) and ADIPO-IR (P<0.0001). However, neither were affected by the thiamine treatment (Fig. 3D,E, Table 2).
Interestingly, although blood glucose levels were lowered by thiamine, hepatic glycogen levels increased (Fig. 3F). Since thiamine did not affect plasma insulin, which together with glucose as a substrate for glycogen, is known to upregulate hepatic glycogen levels (Samuel and Shulman, 2016), the increase in hepatic glycogen by thiamine might indicate improved hepatic sensitivity to insulin. At gene expression levels, no differences were detected between THC and HC animals in genes related to insulin resistance (Fig. 3D,E, Fig. S4) or to glycogen formation (Fig. 3G), suggesting that post-translational effects that are known to regulate hepatic glycogen metabolism (Roach et al., 2012) are involved.
Thiamine treatment prevented diet-induced hepatic steatosis
The average hepatic-fat content determined for HC sheep (8.1%; Fig. 4A) was virtually identical to that observed previously (Kalyesubula et al., 2020). Treatment with thiamine, however, had a strong effect on the hepatic-fat content, as it was substantially lower in the THC animals (4.8%, P<0.0001; Fig. 4A). Notably, the THC fat content was below the typical 5.5% threshold for fatty liver (Szczepaniak et al., 2005), and statistically similar to the levels in LC sheep (3.9%, P=0.164). Hepatocellular steatosis, either macrovesicular or microvesicular, which is correlated with advanced histology of MAFLD (Tandra et al., 2011), was significantly increased in HC compared to both LC and THC animals (Fig. 4B,C). Interestingly, the remarkable reduction in intrahepatic fat caused by thiamine was not associated with a decrease in whole-body insulin resistance (Fig. 3D). Whether the decrease in hepatic fat by thiamine involves a reduction in hepatic insulin resistance remains unknown. This possibility is, however, consistent with the observed increase of hepatic glycogen as a surrogate for insulin sensitivity (Petersen et al., 1998).
Consistent with the previous observation by Kalyesubula et al. (2020), the HC diet increased the hepatic index (liver weight/BW) compared to the LC diet, indicative of disproportional growth of the liver (hepatomegaly). Thiamine, however, had no apparent macroscopic effect on liver growth (Fig. 4D, Table 2) although, microscopically, the size of hepatocytes was increased in THC compared to LC and HC livers (Fig. 4E). Although the mechanisms remain to be investigated, it is plausible that the increase in glycogen content due to thiamine contributed to these observations, since hepatomegaly is associated with increases in either hepatic fat or hepatic glycogen content (Reid, 2001; Sherigar et al., 2018).
HC diet decreased hepatic expression of genes involved in mitochondrial catabolism
Mammalian regulation of energy expenditure is primarily mediated by sensing of the cellular levels of adenosine monophosphate (AMP) and NAD+, respectively, by AMP-activated protein kinase (AMPK) and NAD-dependent protein deacetylase sirtuin-1 (SIRT1). In the setting of low-caloric intake, the resulting increased levels of AMP and NAD+ allosterically activate AMPK and SIRT1, respectively. Activation of these evolutionarily-conserved sensors turns on signaling cascades that stimulate catabolic and inhibit anabolic processes. Peroxisome proliferator-activated receptor gamma coactivator-1-alpha (PPARGC1A), a master regulator of mitochondrial biogenesis, is directly targeted by SIRT1 and AMPK to stimulate mitochondrial oxidative processes in response to energy requirements and nutrient availability (Cantó and Auwerx, 2009).
In our current study, SIRT1 expression was similar in the three treatment groups. However, overnourished sheep raised on the HC diet exhibited decreased gene expression of PRKAA2, PPARGC1A and peroxisome proliferator-activated receptor alpha (PPARA) (P=0.05; Fig. 5A). Reduced expression of this molecular network, is expected to promote de novo lipogenesis and to inhibit fatty acid oxidation (Smith et al., 2016), which is consistent with the increased hepatic steatosis observed in HC animals, both in our present study and in a previous one (Kalyesubula et al., 2020). Thiamine, however, had no effect on the expression levels of these three genes.
Thiamine-induced alterations in the expression of hepatic genes favored the inhibition of fat storage
Under conditions of energy abundance, as caused by the HC diet, newly derived TG, resulting from hepatic synthesis and liver uptake of circulating lipoproteins, can be either secreted into the bloodstream in very-low-density lipoprotein (VLDL) particles or incorporated into cytosolic lipid droplets (LDs) for storage as intrahepatic fat (Alves-Bezerra and Cohen, 2018). Expansion or reduction of the fat content within LDs is dynamically regulated by LD-associated proteins (Gluchowski et al., 2017), and by the availability of cytosolic TG, which is partly controlled by the lipidation of VLDL particles through microsomal triglyceride transfer protein (MTP) encoded by the MTTP gene. Hepatic steatosis has been associated with genetic defects in both MTP and apolipoprotein B-100 (APOB), the hepatic VLDL lipoprotein (Berriot-Varoqueaux et al., 2000; Tanoli et al., 2004). In the current study, thiamine increased the abundance of the MTTP transcripts compared with those in the untreated HC group (P=0.001; Fig. 5B). No effects were detected on APOB transcript levels.
Perilipins are the predominant proteins in hepatocellular LD proteins (Alves-Bezerra and Cohen, 2018). They are associated to the LD surface, stabilizing the structure of LDs and controlling substrate availability for certain LD-associated enzymes (Kimmel and Sztalryd, 2016). Perilipin 2 (PLIN2), which positively correlates with hepatic steatosis (Chang et al., 2006; Fukushima et al., 2005; Motomura et al., 2006; Najt et al., 2016), is one of the best-characterized LD proteins associated with fatty liver disease (Okumura, 2011). We found that, in contrast to animals fed the LC diet, the abundance of perilipin 2 transcripts was significantly increased in those fed the HC diet (P<0.0001; Fig. 5B), and that thiamine treatment substantially lowered the transcript levels (P=0.002; Fig. 5B). These findings are in accordance with earlier studies, showing that both mRNA and protein levels of PLIN 2 increase with hepatic accumulation of TG (Motomura et al., 2006; Pawella et al., 2014; Straub et al., 2008), whereas inactivation of the perilipin 2 gene lowered hepatic steatosis (Chang et al., 2006; Greenberg et al., 2011).
Low-calorie diet increased expression of genes involved in liver uptake of fatty acids
A variety of proteins associated with hepatic steatosis have been implicated in the liver uptake of circulating NEFA, including platelet glycoprotein 4 (CD36, also known as fatty acid translocase), caveolin, and fatty acid transport protein (SLC27A, also known as FATP) complexes that possess very-long-chain acyl-CoA synthase activity (Alves-Bezerra and Cohen, 2018). Consistent with the elevated plasma concentrations of NEFA in the LC group (Fig. 3C), abundance of SLC27A6 (P=0.0008) and SLC27A5 (P=0.03) mRNAs was higher in these animals (Fig. 5C). Since PPAR-α positively regulates transcription of NEFA transporters (Pawlak et al., 2015), these data are consistent with the observed increased PPARA gene expression of Fig. 5A. Thiamine did not have an effect on the expression of this energy-sensing axis (Fig. 5A), on genes involved in lipogenesis (Fig. 5D) or on NEFA transporters (Fig. 5D).
Hepatic fat accumulation was associated with altered gene expression of proinflammatory cytokines and antioxidants; some increases in gene expression were reversed by thiamine treatment
As a well-documented factor in the pathogenesis of obesity, metabolic syndrome and insulin resistance, inflammation also plays a role in the progression of MAFLD (Ibrahim et al., 2018). In addition to the common histological signs of steatohepatitis, inflammation in MAFLD patients is manifested by increased circulation levels of proinflammatory cytokines and leukocytes that can infiltrate the liver to fuel local and systemic inflammatory processes (Tilg et al., 2020). In our study, HC-fed sheep exhibited increased mRNA levels of C-C motif chemokine 2 and interleukin-8 (CCL2 and CXCL8, respectively) (P=0.05; Fig. 6A) in circulating leukocytes as compared to LC-fed animals, but thiamine treatment reversed the dietary effect on CXCL8 expression (P=0.05; Fig. 6A). Leukocytes of HC- or THC-fed animals showed no effect on the expression levels of interleukin-1 beta (IL1B), tumor necrosis factor (TNF) and interferon gamma (IFNG).
In the liver, thiamine lowered the expression of TNF (P=0.005; Fig. 6B) but did not significantly alter the mRNA levels of NFKB1, IL1B, CCL2 and CXCL8. The HC diet increased expression of pentraxin 3 (PTX3) compared with the LC diet (P=0.01; Fig. 6B).
Overnutrition and hepatic steatosis are associated with an increase in reactive oxygen species and oxidative stress, which may decrease levels of endogenous enzymes that act as antioxidants (Spahis et al., 2017; Videla et al., 2004). Consistently, expression of catalase was decreased as a result of the HC diet (P=0.005; Fig. 6C) but not affected any further upon treatment with thiamine. Expression levels of superoxide dismutase 2 (SOD2) (P=0.02; Fig. 6C), however, were increased upon treatment with thiamine. No treatment effects were detected on the expression of glutathione peroxidase 1 (GPX1).
Hepatic steatosis is the hallmark of the MAFLD global metabolic epidemic. In this study, we set out to investigate the potential of high-dose thiamine therapy to ameliorate overnutrition-induced hepatic steatosis in a sheep model. The main metabolic phenotypes of this model, i.e. hyperglycemia, hyperinsulinemia, insulin resistance and hepatic steatosis, were virtually identical to those observed in a previous study (Kalyesubula et al., 2020).
We found that thiamine reduced the hepatic-fat content dramatically, decreased blood glucose levels, and increased the hepatic glycogen content. The weekly dose of thiamine employed here, i.e. 900–1500 mg per animal, is likely to be realistic when investigating its effect in other species of similar body weight, i.e. ∼70 kg (Table S2), such as humans. Yet, clearly additional investigations are required to determine the minimal effective dose, duration and frequency of therapy.
Interestingly, the robust effect of thiamine on hepatic steatosis was not accompanied by an effect on whole-body or adipose insulin resistance (Fig. 3D,E), providing evidence that hepatic steatosis may be targeted directly and independently. Whether hepatic insulin resistance is involved in the development of steatosis or modulated by thiamine remains to be investigated. Yet, the increase in hepatic glycogen content upon thiamine treatment (Fig. 3F) is consistent with a reduction in hepatic insulin resistance.
To investigate the involvement of potential metabolic pathways in mediating the observed dietary and thiamine-treatment phenotypes, we performed ex vivo studies on postmortem liver extracts. Although these have the capacity to sensitively detect subtle molecular differences between treatments, it is important to realize that postmortem liver extracts reflect a final cumulative picture that highlights lasting and sustained rather than temporary effects.
The change in liver activity of α-KGDH, a key enzyme in setting the TCA-cycle turnover rate, in response to exogenous TPP (Fig. 2B), suggests that animals raised on the HC diet had relatively low levels of hepatic TPP. Consequently, the higher hepatic TPP levels in the thiamine-treated animals may have, potentially, boosted mitochondrial catabolism of pyruvate and acetyl-CoA, by increasing both the catalytic activity of PDH and the oxidative capacity of the TCA cycle. This is consistent with the observed decrease in blood glucose levels and reduced hepatic fat observed in thiamine-treated animals. Interestingly, at gene-expression levels, thiamine treatment might have also increased the glycolytic flux, since abundance of GAPDH mRNA also increased.
In response to cellular energy levels, the AMPK/PPGC-1α/PPAR-α axis orchestrates gene expression to trigger both fatty acid β-oxidation and inhibition of lipogenesis. Whereas the functionality of this energy-sensing axis is mediated by post-translational phosphorylation signals, transcriptional adaptations of the genes involved seems physiologically important and relevant to overnutrition, since decreased expression levels are associated with increased dietary consumption, insulin resistance and metabolic dysfunction (Cantó and Auwerx, 2009; Herzig and Shaw, 2018). Accordingly, strategies to combat insulin resistance, metabolic syndrome and hepatic steatosis have been proposed based on stimulation of this axis (Gariani et al., 2016; Ruderman et al., 2013; Smith et al., 2016).
In our current study, the overnourished animals raised on the HC diet also exhibited decreased expression of AMPK/PPGC-1α/PPAR-α (Fig. 5A), which is consistent with their increased insulin resistance. Moreover, since reduced AMPK signaling is expected to decrease fatty acid oxidation and to increase lipogenesis, these molecular observations are in line with the steatotic phenotype of the HC animals.
Although thiamine robustly decreased the hepatic-fat content (Fig. 4), we found no direct evidence for increased sensitivity to insulin or increased gene expression regarding the AMPK energy-sensing axis (Fig. 5A). This suggests that the mechanism of steatosis reduction or its inhibition by thiamine does not involve insulin sensitization and/or regulation of AMPK signaling on a transcriptional level. This is consistent with the observation that transcription of lipogenic genes was not significantly altered by thiamine (Fig. 5D). The possibility that thiamine is involved in post-translational regulation of AMPK signaling remains to be investigated.
Surprisingly, no effects of thiamine were detected on expression of tested genes involved in lipogenesis and mitochondrial oxidation. However, thiamine-treated animals presented with altered expression of genes involved in LD stability and VLDL lipidation. In particular, transcripts levels of perilipin 2 – which is essential for the structural integrity of LDs and has been shown to be positively correlated with hepatic steatosis (Alves-Bezerra and Cohen, 2018; McIntosh et al., 2012; Motomura et al., 2006; Najt et al., 2016) – were substantially decreased. Notably, this effect of thiamine reversed the strong dietary effect of the HC diet in increasing perilipin 2 transcripts, thus reflecting the observed pattern of steatosis in LC, HC and THC animals. The simultaneous effect of thiamine in increasing mRNA levels of MTTP, which is essential for hepatic VLDL lipidation, might further contribute to the depletion of TG from cytosolic LDs and their export to extrahepatic tissues. In line with this, the liver-specific loss of perilipin 2, which alleviates hepatic steatosis, was also associated with an increase in MTP (Najt et al., 2016). The coupling of low levels of PLIN2 with high levels of MTP might serve as a customary module for the efficient depletion of intrahepatic fat.
Progressive liver disease has not been established for the current sheep model, which is more likely to resemble non-alcoholic FL (NAFL). Therefore, it is unlikely that inflammation played a main role in the development of steatosis in this model or in its reversal by thiamine. Nevertheless, since both inflammation and oxidative stress have been extensively documented in obesity and MAFLD (Ibrahim et al., 2018; Tilg et al., 2020), we investigated their association with overnutrition and thiamine intervention, by comparing transcript levels of common proinflammatory cytokines and antioxidants.
Overnourished steatotic sheep displayed increased expression levels of CCL2 and CXCL8 in circulating leukocytes, and of PTX3 in liver. Treatment with thiamine had an effect in the opposite direction, i.e. it reduced the expression of CXCL8 in leukocytes and TNF in liver. Interestingly, treatment of mice with thalidomide, which inhibits production of TNF-α, showed improvements regarding hepatic alterations caused by a high-fat diet (de Fraia Pinto et al., 2010). With regard to oxidative stress, the HC diet decreased the gene expression levels of catalase with thiamine not having any effect; however thiamine did increase the expression of SOD2, which, potentially, increases antioxidative capacity.
In this study, we demonstrated the potential of pharmacological thiamine therapy to address hepatic steatosis resulting from overnutrition. Differential gene expression analyses indicate that reduction of steatosis by thiamine may involve destabilization of LDs and increased VLDL lipidation, rather than insulin sensitization. It will, therefore, be valuable to investigate the clinical benefits of thiamine therapy in the management of hepatic steatosis and of combination therapies using both thiamine and insulin sensitizers for management of FL disorders that involve insulin resistance, such as MAFLD.
MATERIALS AND METHODS
Animals and experimental design
All animal studies were approved by the Animal Care Committee of the Volcani Center (Permit 790/18IL), and performed at the Volcani Center experimental sheep farm (Rishon LeZion, Israel). The in vivo investigations were started in August and ended in December 2018, corresponding approximately to the end-of-summer through mid-winter in Israel. Animals were maintained in open-shed pens, protected from direct sunlight and rain, with adequate ventilation and daylight. Following weaning at ∼45 days after birth, all male lambs within one crop (a cohort of ∼250 born around June), of the Afec-Assaf breed (Gootwine et al., 2008), were fed a high-calorie (HC) concentrate-based diet (Table S1). Two weeks later, 36 lambs (2.0±0.04 months old, 25.6±0.87 kg body weight) were randomly assigned to three treatment groups (n=12 each): (i) HC diet (control for thiamine effects), (ii) HC diet plus thiamine (THC), and (iii) low-calorie (LC) diet (Table S1) as a reference group of lean livers and a control for the dietary effects (see experimental flowchart, Fig. 1). Animals were provided ad libitum with their respective group rations, with free access to fresh drinking water. The group feeds and leftovers were weighed weekly. The group means of daily energy intake were 5.16, 5.29 and 3.50 MCal of metabolizable energy for HC, THC and LC animals, respectively (Table S1). These dietary treatments were provided for the entire experimental duration (135 days); pharmacological treatments were given only for the last 85 days.
THC animals were given subcutaneous injections of thiamine hydrochloride (Duchefa Biocemie, Haarlem, The Netherlands) at 300 mg/animal, dissolved in 2 ml of filter-sterilized 0.9% saline solution, administered three times weekly from day 50 onwards and five times weekly from day 93 onwards, to compensate for the increase in the lambs’ body weights. LC and HC lambs were administered with equal volumes of 0.9% saline to control for the potential stress effects of the subcutaneous injection.
Blood, plasma and liver sampling
Blood was drawn weekly from the jugular vein, and glucose concentrations were measured using a FreeStyle Optium glucometer (Abbot Diabetes Care Ltd., Oxfordshire, UK) (Pichler et al., 2014). Twice monthly, plasma was isolated from 5 ml freshly drawn blood as described (Kalyesubula et al., 2020). On day 130, the animals were fasted for 24 h with free access to water to evaluate blood and plasma fasting parameters. Before fasting, the body condition score (BCS) (Kenyon et al., 2014) was determined, and heart girth, withers height and body length were measured. Fasting plasma samples were stored at −20°C until biochemical analyses. Individual weights were measured weekly.
At day 135, animals were slaughtered at a local abattoir, and their livers immediately harvested and weighed. Samples of ∼10 g from the left lobe of each liver were placed in cryo-tubes, flash-frozen in liquid nitrogen and then stored at −80°C until taken for molecular analyses. Another ∼200 g of the left lobe of each liver was stored in a zip-lock bag at −20°C until used for other analyses. Liver glycogen content was quantified as described (Kalyesubula et al., 2020).
Fat content analysis
Hepatic fat content analysis was performed using the improved Folch method (Mopuri et al., 2021). Briefly, triplicates of ∼1 g liver tissue were sampled from the frozen left lobe. The exact wet weight of each piece was determined after thawing and dehydrating the excess moisture on a Whatman filter paper for 10 min at 25°C. Each sample was mechanically homogenized in 25 ml chloroform:methanol (2:1) solution, followed by sonication on ice, overnight agitation at 25°C and 10 min centrifugation at 3000 g. For removal of polar and semi-polar lipids, 4 ml of 0.9% NaCl was added to the supernatant, and the mixture was vortexed, then centrifuged at 2500 g for 10 min. The upper phase was discarded, and the residual interface rinsed twice with 4 ml of 50% methanol. The lower chloroform phase containing the fat (TG and cholesterol esters) was collected and evaporated in a rotary evaporator under vacuum. The residual fatty phase was oven-dried at 45°C for 2.5 h to remove residual moisture. The fat weight was determined, and the hepatic-fat content was computed as the percentage of the wet liver weight.
Sample preparation, fixation and staining were performed as described (Kalyesubula et al., 2020). Analyses of Hematoxylin-Eosin (H&E) and periodic acid–Schiff (PAS)-stained sections were examined blindly by a veterinary pathologist. The assessment was performed by counting hepatocytes showing either macrovesicular or microvesicular steatosis at ×200 magnification in three randomly selected fields. Scores of 0, 1, 2 or 3 were assigned to samples presenting <5%, 5–33%, >33–66% or >66% steatotic hepatocytes, respectively. Data are presented on a frequency plot (Fig. 4C), and differences between treatments were explored by univariate χ2 analysis.
Assessment of the size of hepatocytes was made by counting their number under a fixed microscopic field at ×200 magnification, which is inversely related to their size. Each sample was observed at three homogeneous zones of liver tissue consisting of hepatocytes and no vessels; the triplicate-average count was used for statistical analysis by ANOVA and contrast statistics using Student's t-tests.
Biochemical analysis of plasma
Plasma TG were measured using the Cobas C 111 analyzer (Roche Diagnostics, Rotkruez, Switzerland). Plasma NEFA concentration was determined using a NEFA kit (Wako Chemicals, GmbH, Neuss, Germany), and plasma insulin was determined using a radioimmunoassay kit (Coat-A-Count insulin; Diagnostic Products, Los Angeles, CA). Plasma thiamine concentrations were analyzed using a Vitamin B1 ELISA kit (Aviva Systems Biology; San Diego, CA). Plasma leptin activity was determined by cell-based bioassay in HEK-293T cells expressing exogenous full-length leptin receptor (LEPR) cDNA with firefly luciferase as an intracellular reporter gene, as described (Seroussi et al., 2016).
Determination of mRNA by quantitative PCR
For isolation of RNA from leukocytes, blood was collected from sheep on day 126 by venipuncture into EDTA-coated tubes and kept on ice. RNA extraction was carried out using the Norgen leukocyte RNA purification kit (Norgen Biotek Corp., Ontario, Canada). DNAase treatment was performed using Promega RQ1 RNAase-Free DNase (Promega, Madison, WI, USA). cDNA was synthesized from 500 ng total RNA using a Revert Aid RT-PCR Kit (Thermo Fisher Scientific, USA).
For isolation of RNA from liver tissue, the Norgen animal tissue RNA purification kit (Norgen Biotek Corp., Ontario, Canada) was used following the manufacturer's instructions. cDNA was synthesized from 1 µg total RNA using a Revert Aid RT-PCR Kit (Thermo Fisher Scientific, USA), using the Applied Biosystems 2720 Thermal Cycler (Thermo Fisher Scientific, USA) following the manufacturer's instructions. RT-qPCR analysis was carried out using 5× HOT FIREPol EvaGreen qPCR Supermix (Solis BioDyne, Tartu, Estonia). The reaction mixture contained: 4 µl of cDNA, 0.3 µl of each primer designed using NCBI Primer Blast (Table S3), 4 µl of 5× HOT FIREPol EvaGreen qPCR Supermix, completed with ultra-pure water (Biological Industries, Kibbutz Beit Ha'emmek, Israel) to a final volume of 20 µl. RT-qPCR was carried out using a Rotor-Gene Q PCR cycler (Qiagen, Hilden, Germany) using the following PCR protocol: 95°C for 12 min, 40 cycles at 95°C for 15 s, 60 cycles at 95°C for 20 s, 72°C for 20 s.
Relative gene expression was computed by using the ΔΔCT method (Livak and Schmittgen, 2001), with the mean of the HC group as the normalizer. For leukocytes, the geometric mean of two reference genes (GAPDH and YWHAZ; Table S3) was employed; for liver, the geometric mean of three reference genes (YWHAZ, PPIA and RPL19; Table S3) was employed.
Data for continuous dependent variables (glucose, insulin, TG, NEFA concentration and weight; Table 1) were analyzed by repeated measures ANOVA (for variables measured repeatedly over time) with the linear mixed model approach in JMP (Version 14.0.0, SAS Institute Inc., Cary, NC, 2016). The model included Treatment (LC vs HC – for dietary effects) or (THC vs HC – for the thiamine effects) as a between-subject fixed factor, Time (from treatment initiation) as a nominal within-subject fixed factor, Treatment×Time interaction and Individual Animal as a random factor nested within Treatment. For the effect of thiamine, only data obtained when thiamine treatment was initiated (day 50 onwards), were taken into consideration. The distribution of model residuals was visually confirmed for normality. Post-hoc pairwise comparisons between treatments at specific time points were carried out using contrast statistics using Student's t-test; significance was corrected for multiple comparisons by using the Holm–Bonferroni method.
Differences between treatments for other response variables that lack the time dimension (as in Table 2), were determined by one-way ANOVA. Selected a priori comparisons to investigate the effects of diet (HC vs LC) and of thiamine (HC vs THC) were carried out by using contrast statistics using Student's t-tests. Two-tailed P-values are reported throughout. Data are presented as means±standard errors (±s.e.), unless otherwise stated. A significance threshold level of α=0.05 was employed.
We thank Hilary Voet (Hebrew University, Jersusalem, Israel) for advice regarding statistics, Elisha Gootwine (Volcani Center - ARO, Rishon LeZion, Israel) for valuable discussions, and Israel Silman (Weizmann Institute, Rehovot, Israel) for critical reading and editing of this paper.
Conceptualization: S.B., H.D.; Methodology: H.D.; Validation: H.D.; Formal analysis: M.K., R.M., H.D.; Investigation: M.K., R.M, J.A., A.R., S.Y., N.E., H.D.; Resources: H.D.; Data curation: M.K., H.D.; Writing - original draft: H.D.; Writing - review & editing: M.K., R.M., S.B., U.M., H.D.; Visualization: H.D.; Supervision: H.D.; Project administration: H.D.; Funding acquisition: H.D.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
An institutional patent application regarding the potential use of thiamine for the management of fatty liver-related disorders has been filed by H.D. and S.B. All other authors declare no competing interests.